{
    "startDate": "2021-03-01",
    "endDate": "2021-05-31",
    "year": "2022",
    "quarter": "Q1",
    "symbol": "BZYR",
    "data": {
        "bs": [
            {
                "label": "Accrued liabilities",
                "concept": "AccruedLiabilitiesCurrent",
                "unit": "usd",
                "value": 32801
            },
            {
                "label": "Accounts payable",
                "concept": "AccountsPayableCurrent",
                "unit": "usd",
                "value": 30441
            },
            {
                "label": "Commitments and contingencies",
                "concept": "CommitmentsAndContingencies",
                "unit": "usd",
                "value": "N/A"
            },
            {
                "label": "TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT",
                "concept": "LiabilitiesAndStockholdersEquity",
                "unit": "usd",
                "value": 2009
            },
            {
                "label": "CURRENT AND TOTAL LIABILITIES",
                "concept": "Liabilities",
                "unit": "usd",
                "value": 63242
            },
            {
                "label": "TOTAL CURRENT ASSETS",
                "concept": "AssetsCurrent",
                "unit": "usd",
                "value": 2009
            },
            {
                "label": "Prepaids",
                "concept": "PrepaidExpenseCurrent",
                "unit": "usd",
                "value": 1415
            },
            {
                "label": "TOTAL STOCKHOLDERS' DEFICIT",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": -61233
            },
            {
                "label": "TOTAL STOCKHOLDERS' DEFICIT",
                "concept": "StockholdersEquity",
                "unit": "usd",
                "value": -61233
            },
            {
                "label": "Retained deficit",
                "concept": "RetainedEarningsAccumulatedDeficit",
                "unit": "usd",
                "value": -125178110
            },
            {
                "label": "Additional paid-in capital",
                "concept": "AdditionalPaidInCapitalCommonStock",
                "unit": "usd",
                "value": 124985428
            },
            {
                "label": "Cash and cash equivalents",
                "concept": "CashAndCashEquivalentsAtCarryingValue",
                "unit": "usd",
                "value": 594
            },
            {
                "label": "Common stock, $.001 par value; 200,000,000 shares authorized; 131,448,444 issued and outstanding at May 31, 2021 and February 28, 2021",
                "concept": "CommonStockValue",
                "unit": "usd",
                "value": 131449
            },
            {
                "label": "TOTAL ASSETS",
                "concept": "Assets",
                "unit": "usd",
                "value": 2009
            }
        ],
        "cf": [
            {
                "label": "Prepaids",
                "concept": "IncreaseDecreaseInPrepaidExpense",
                "unit": "usd",
                "value": 521
            },
            {
                "label": "NET INCREASE (DECREASE) IN CASH",
                "concept": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
                "unit": "usd",
                "value": 532
            },
            {
                "label": "NET CASH USED IN OPERATING ACTIVITIES",
                "concept": "NetCashProvidedByUsedInOperatingActivities",
                "unit": "usd",
                "value": -84435
            },
            {
                "label": "Accounts payable",
                "concept": "IncreaseDecreaseInAccountsPayable",
                "unit": "usd",
                "value": -2071
            },
            {
                "label": "FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D.",
                "concept": "bzyr:ClinicalTrialExpensesPaid",
                "unit": "usd",
                "value": 215926
            },
            {
                "label": "Net loss",
                "concept": "NetIncomeLossAvailableToCommonStockholdersBasic",
                "unit": "usd",
                "value": -316283
            },
            {
                "label": "Net loss",
                "concept": "NetIncomeLossAvailableToCommonStockholdersBasic",
                "unit": "usd",
                "value": -316283
            },
            {
                "label": "Net loss",
                "concept": "NetIncomeLossAvailableToCommonStockholdersBasic",
                "unit": "usd",
                "value": -316283
            },
            {
                "label": "NET CASH PROVIDED BY FINANCING ACTIVITIES",
                "concept": "NetCashProvidedByUsedInFinancingActivities",
                "unit": "usd",
                "value": 84967
            },
            {
                "label": "Contribution of capital",
                "concept": "ProceedsFromContributedCapital",
                "unit": "usd",
                "value": 84967
            },
            {
                "label": "Accrued liabilities",
                "concept": "IncreaseDecreaseInAccruedLiabilities",
                "unit": "usd",
                "value": 18514
            }
        ],
        "ic": [
            {
                "label": "Basic and diluted loss per common share",
                "concept": "EarningsPerShareBasicAndDiluted",
                "unit": "usd/shares",
                "value": 0.0
            },
            {
                "label": "TOTAL OPERATING EXPENSES",
                "concept": "OperatingExpenses",
                "unit": "usd",
                "value": 316283
            },
            {
                "label": "Research and development",
                "concept": "ResearchAndDevelopmentExpense",
                "unit": "usd",
                "value": 231946
            },
            {
                "label": "Loss before provision for income tax",
                "concept": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
                "unit": "usd",
                "value": -316283
            },
            {
                "label": "Weighted average number of common shares outstanding",
                "concept": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
                "unit": "shares",
                "value": 131448444
            },
            {
                "label": "Operating loss",
                "concept": "OperatingIncomeLoss",
                "unit": "usd",
                "value": -316283
            },
            {
                "label": "NET LOSS",
                "concept": "NetIncomeLossAvailableToCommonStockholdersBasic",
                "unit": "usd",
                "value": -316283
            },
            {
                "label": "NET LOSS",
                "concept": "NetIncomeLossAvailableToCommonStockholdersBasic",
                "unit": "usd",
                "value": -316283
            },
            {
                "label": "NET LOSS",
                "concept": "NetIncomeLossAvailableToCommonStockholdersBasic",
                "unit": "usd",
                "value": -316283
            },
            {
                "label": "General and administrative",
                "concept": "GeneralAndAdministrativeExpense",
                "unit": "usd",
                "value": 84337
            },
            {
                "label": "Income tax expense",
                "concept": "OtherNoncashIncomeTaxExpense",
                "unit": "usd",
                "value": 0
            }
        ]
    }
}